A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...

These glasses allow people with macular degeneration to see complete objects by banishing pesky blind spots using dozens of ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

On completion of the scans and tests, he said: “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD – it’s very common.” My grandmother suffered.

Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according to a real-world study presented at Retina 2025. Ferhina S. Ali, MD, MPH, ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...

A multidisciplinary team of researchers from the Istituto Italiano di Tecnologia (IIT-Italian Institute of Technology) and ...